TITLE

Four years later, roadblocks to AIDS drugs overcome

AUTHOR(S)
Silversides, Ann
PUB. DATE
August 2008
SOURCE
CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p415
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the scheduled shipment of low-cost life-saving AIDS drugs to Rwanda. In May 2004, Canada implemented a World Trade Organization (WTO) agreement intended to get low-cost, life-saving drugs to the developing countries. According to spokesperson Elie Betito, Apotex Inc. is expected to supply AIDS drugs to treat 21,000 Rwandans for a year. The WTO agreement allowed generic drug companies to apply for licences to patented drugs to manufacture generic drugs to developing countries.
ACCESSION #
33923050

 

Related Articles

  • Production and export of generic medicines under the TRIPS Agreement.  // WHO Drug Information;2006, Vol. 20 Issue 1, p22 

    The article presents information on the Ministerial Declaration on the TRIPS Agreement and Public Health adopted by WTO Members at the WTO Ministerial Conference in Doha in November 2001. The system permits countries to import generic medicines from a foreign producer. The most significant...

  • Delivery past due: global precedent set under Canada's Access to Medicines Regime. Elliott, Richard // HIV/AIDS Policy & Law Review;Jul2008, Vol. 13 Issue 1, p1 

    The article provides an overview of developments under Canada's Access to Medicines Regime (CAMR) and identifies key reforms needed to streamline the regime so that it can be used easily to address public health problems in developing countries. It discusses the World Trade Organization (WTO)...

  • Brazil and India clash with EU over seizure of generic drugs. Zarocostas, John // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/14/2009, p371 

    The article reports on a confrontation between the European Union and India and Brazil which was seen in the World Trade Organization in February of 2009. The confrontation was a result of a decision from Dutch customs authorities to detain a shipment of losartan potassium, a generic version of...

  • Will they deliver treatment access?: WTO rules and Canada's law on generic medicine exports. Elliott, Richard // HIV/AIDS Policy & Law Review;Dec2006, Vol. 11 Issue 2/3, p13 

    The article discusses the compulsory and complicated laws for exporting generic medicines out of Canada. The World Trade Organization's decision forces generic companies through unnecessary red tape to get a licences to manufacture and export each patented drug. Developing countries need simple...

  • The EU has adopted legislation to enable access to safe and effective generic medicines in developing countries.  // PharmacoEconomics & Outcomes News;5/20/2006, Issue 503, p29 

    The article reports on the adoption of a legislation to enable access to safe and effective generic medicines in developing countries by the European Union, according to the "British Medical Journal." Firms will be given licences to produce generic medicines for export to low-income countries...

  • WTO approves TRIPS amendment on importing under compulsory licensing. Herget, Greg // HIV/AIDS Policy & Law Review;Apr2006, Vol. 11 Issue 1, p23 

    The article reports on the amendment of the Trade Related Aspects on Intellectual Property Rights (TRIP) Agreement done by the World Trade Organization (WTO) in August 2003. The original TRIP Agreement allowed governments to issue compulsory licenses authorizing a manufacturer to make, use and...

  • European Union and India Battle over Free Trade Agreement. Sutton, Stephanie // BioPharm International;Apr2011, Vol. 24 Issue 4, p12 

    The article reports on the conflict between the European Union and India over Free Trade Agreement (FTA) negotiations on intellectual property provisions on medicines.

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • recommended International Non-proprietary Name.  // Royal Society of Medicine: Medicines;2002, p470 

    This article presents information on recommended International Non-Proprietary Name (rINN). The rINN is the official name of a generic drug chosen by an international commission. In most cases it is the same as the BAN, but the British is moving towards the universal use of entirely fINN names....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics